| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.072 | 0.06 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.11 | 0.06 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.06 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.072 | 0.06 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.13 | 0.06 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.06 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.06 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.06 |